Direct answer: regulatory strategy should start at the idea stage, not after you build a prototype.

If you wait until the device is engineered to think about FDA requirements, you’ve already made decisions that may be expensive—or impossible—to fix later.

Why Regulatory Strategy Starts at Ideation

From the very beginning, the U.S. Food and Drug Administration does not look at your device as “cool technology.”
They look at it as a risk-control system meant to protect patients.

That perspective affects early decisions more than most founders realize.

1. Intended Use Drives the Entire Regulatory Path

Your intended use determines:

Device classification (Class I, II, or III)

Whether you need a 510(k), De Novo, or PMA

The type and amount of evidence FDA will expect

Even small wording choices can push your device into a higher-risk category. Changing intended use later often means repeating testing or restarting the regulatory process entirely.

This is why intended use should be pressure-tested before design begins—not after.

2. Design Choices Are Regulatory Choices

Early design decisions have regulatory consequences, whether you plan for them or not:

Materials affect biocompatibility testing

Software functions affect software level of concern

User population affects human factors requirements

Connectivity affects cybersecurity expectations

When these issues are ignored early, engineering teams often design devices that work technically—but are difficult to justify from a regulatory standpoint.

3. Evidence Cannot Be Added After the Fact

FDA expects safety and performance evidence to be:

Planned in advance

Linked to identified risks

Traceable to design inputs

Trying to “add” regulatory evidence after a prototype is built often leads to:

Redundant or invalid studies

Data FDA will not accept

Costly delays and redesigns

If evidence planning is not built in early, you are setting yourself up for rework.

Where Kandih Comes In

This is where Kandih Group supports founders best—before engineering decisions harden.

Kandih helps innovators:

Pressure-test device ideas against FDA expectations

Clarify intended use without triggering regulatory creep

Identify regulatory risks tied to materials, software, and use

Build an evidence strategy that aligns with FDA standards

Avoid redesigns, repeat testing, and wasted capital

In short: we help you design with the FDA in mind, instead of defending decisions later.

Bottom Line

Regulatory strategy is not a final step.
It is a design input.

Starting regulatory strategy at ideation:

Saves time

Saves money

Reduces regulatory risk

Increases the chance your device reaches patients

If speed matters, start early. If success matters, start smart.

References

FDA – Classify Your Medical Device
https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device

FDA – Quality System Regulation (21 CFR Part 820)
https://www.fda.gov/medical-devices/quality-system-qs-regulation-medical-device/current-good-manufacturing-practice-cgmp

FDA – Design Controls Guidance for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-controls-medical-devices

FDA – Recognized Consensus Standards (ISO 14971 Risk Management)
https://www.fda.gov/medical-devices/standards-and-conformity-assessment-program/recognized-consensus-standards